ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Response to belimumab among patients with refractory lupus nephritis: a real-world observational retrospective multicenter study

Zhang, Shuoyang; Qiu, Qian; Zeng, Shan; Li, Hao; Xu, Liujing; Jie, Ligang; Hu, Xuejun; Xiao, Youjun; Chen, Dongying; Zhan, Zhongping; Liang, Liuqin*; Yu, Qinghong*; Xu, Hanshi*南方医科大学; 中山大学; 1
CLINICAL RHEUMATOLOGY2023-11-20DOI: 10.1007/s10067-023-06817-z
6阅读
引用收藏
分享

摘要

Objectives Belimumab is a biological agent approved for the treatment of active lupus nephritis (LN), but its efficacy on refractory lupus nephritis (LN) is unknown. This study aims to evaluate the efficacy and safety of belimumab in Chinese patients with refractory LN.Methods This multicenter, observational, and retrospective study enrolled patients with refractory LN who failed induction therapy with steroids, cyclophosphamide, mycophenolate, and calcineurin inhibitors and received 24-week belimumab treatment before data analysis. Treatment outcomes include the overall clinical response (physician judgment, disease activity, organ damage) and renal response (complete renal response, partial renal response, no renal response). Laboratory indices and adverse events were recorded as well.Results Of the 45 patients enrolled in the study, 6 (13.3%) achieved complete renal response, 19 (42.2%) achieved partial renal response, and the overall renal response rate was 55.6%. Median rSLEDAI decreased from 12 (IQR 8-12) at baseline to 8 (IQR 4-8) (p < 0.0001), 4 (IQR 4-8) (p < 0.0001) at 12 and 24 weeks. Mean urinary protein decreased more than 50% from 3.2 g/24 h at baseline to 1.0 g/24 h at 24 weeks (p < 0.0001). The conditions of hypoalbuminemia and hypocomplementemia had also gradually improved. The levels of autoantibodies showed a significant downward trend. Additionally, 9 (20.0%) patients successfully reduced the dosage of prednisone to a safe range, and 3 of them achieved their treatment goal of prednisone cessation. The mean prednisone dosage decreased from 32.7 mg/day at baseline to 18.6 mg/day (p < 0.0001), 13.3 mg/day (p < 0.0001) at 12 and 24 weeks. There were 3 adverse events reported, including 2 cases of infection, and 1 case of allergy. No serious events occurred during the follow-up.Conclusions Belimumab is effective and safe when used in clinical practice, which can be considered as an add-on therapy for refractory LN.

学科与关键词

关键词
BelimumabEffectivenessRefractory lupus nephritisSafetySystemic lupus erythematosus
相关
加载中…
  • Efficacy and safety of belimumab in systemic lupus erythematosus patients with severe lupus nephritis requiring renal replacement therapy
    Liu, Diankun; Zhou, Qiang; Wang, Di; Qu, Yuan; Guo, Qihong; Wen, Jing; Yu, Qinghong*; Ai, Jun*Lupus, 2022, 31(12): 1456-1467.被引 1
  • A patient with refractory proliferative lupus nephritis treated with telitacicept: A case report
    Chen, Jing-Wen; Zhan, Jing-Yi; Liang, Si-Ping; Wang, Xiao-Dan; Lin, Chang-Song*; Xu, Qiang*International Journal of Rheumatic Diseases, 2023, 26(7): 1417-1421.被引 4
  • Belimumab in childhood systemic lupus erythematosus: A review of available data
    Chen, Feng; Zheng, Ying; Chen, Xinying; Wen, Zhanfa; Xu, Youjia*; Yang, Jinghua*; Xu, Kaisi*Frontiers in Immunology, 2022, 13: 940416.被引 4
查看全部 →

发表信息

论文状态
公开发表
期刊
CLINICAL RHEUMATOLOGY
发表日期
2023-11-20
DOI
10.1007/s10067-023-06817-z
语言
ENGLISH
成果收录
SCIE
资助标注
Guangzhou Science and Technology Project [201803010042]; Natural Science Foundation of Guangdong Province, China [2022A1515010911]

作者

  • Z

    Zhang, Shuoyang (第一作者)

    1 · sun yat sen univ

  • Q

    Qiu, Qian

    1 · sun yat sen univ

查看全部 13 位作者收起作者
  • Z

    Zeng, Shan

    1

  • L

    Li, Hao

    1 · sun yat sen univ

  • X

    Xu, Liujing

    1 · sun yat sen univ

  • J

    Jie, Ligang

    southern med univ

  • H

    Hu, Xuejun

  • X

    Xiao, Youjun

    1 · sun yat sen univ

  • C

    Chen, Dongying

    1 · sun yat sen univ

  • Z

    Zhan, Zhongping

    1 · sun yat sen univ

  • L

    Liang, Liuqin (通讯)

    1 · sun yat sen univ

  • Y

    Yu, Qinghong (通讯)

    southern med univ

  • X

    Xu, Hanshi (通讯)

    1 · sun yat sen univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417